Generated: May 29, 2017
|Title:||Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma|
|Abstract:||Ocular hypertension and glaucoma can be effectively controlled in primates through topical application of an effective amount of an eicosanoid or an eicosanoid derivative to the surface of an afflicted eye. Eicosanoids, particularly the prostaglandins PGE.sub.2 and PGF.sub.2.alpha., and derivatives thereof, have been found effective in quantities less than about 1000 .mu.g per eye. Ophthalmic compositions containing C.sub.1 to C.sub.5 alkyl esters of PGF.sub.2.alpha. are presently preferred for use in treating ocular hypertension and glaucoma in primates, including man.|
|Inventor(s):||Bito; Laszlo Z. (New York, NY)|
|Assignee:||The Trustees of Columbia University in the City of New York (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0093380||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.